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Evidences  have  been  gathered  from  several  studies  suggest  that  a 
mechanism  involving  an  estrogen-signaling  pathway  may  contribute  to 
modulate risk for Alzheimer’s disease. It was demonstrated that estrogen up-
regulates  the  expression  of  apolipoprotein  E  gene,  which has a  role  in  the 
metabolism of β-amyloid that is related to the progress of Alzheimer’s disease. 
Case-control  studies have  found  an  increased  frequency  of  PvuII  and  XbaI 
polymorphisms  in  affected  subjects.  In  this  study  we  explore  the  possible 
association of different polymorphic forms of human α-estrogen receptor (ER-
a)  with  the  risk  to  late  onset  Alzheimer’s  disease  in  north-west  Iranian 
population. 
We conducted a case-control study in a dataset of 160 LOAD patients 
and  163  healthy  controls  that  have  been  matched  in  gender  and  age.  To 
evaluate the PvuII and XbaI polymorphisms in Alzheimer’s disease we used 
PCR/RFLP  method  and  genotype  frequencies  were  statistically  determined. 
The PCR products prepared from 21 AD cases and 20 healthy controls were 
randomly purified by ethanol precipitation and bidirectionally sequenced. 
The  frequency  of  normal  and  mutated  alleles  for  PvuII  and  XbaI 
locuses respectively, in the LOAD group were significantly higher than those 
in the control group (P<0.001, OR=0.51, 95 % CI 0.35-0.74 for XbaI locus; 
P<0.001, OR=0.41, 95 % CI 0.3-0.57 for PvuII locus). This result suggests that 438                                                                                                            GENETIKA, Vol. 46, No.2, 437-444, 2014 
ERα XbaI and PvuII polymorphism is an additional risk factor for late-onset 
Alzheimer’s disease. 
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INTRODUCTION 
The  most  frequent  neurodegenerative  disease  that  affects  20-30  million  individuals 
worldwide is Alzheimer (SELKOE 2005). It is an untreatable, degenerative and lethal disease and 
usually  diagnosed  in  aged  people  (BROOKMEYER  et  al.  2007).  Alzheimer  is  clinically 
characterized by a progressive loss of memory and cognitive functions in later life (CULPAN et al. 
2003). Inheritance of Alzheimer’s disease (AD) has a complex pattern and several genes and 
environmental  factors  play  roles  in  its  pathogenesis.  Early-onset  (<60  years)  familial  AD 
(EOFAD) almost always inherited as a Mendelian disorder and late-onset AD (LOAD) has less 
apparent or no familial aggregation and usually occur later in life (≥60 years) (GHARESOURAN et 
al. 2013a). There are many genes that because of their potential to alter the risk for late onset 
Alzheimer’s  disease  (LOAD)  have  been  investigated,  but  until  now  only  variations  in  the 
apolipoprotein  E  (APOE)  gene  have  been  always  found  to  be  associated  with  AD,  where 
frequency of the 14 allele in AD cases is 2-3 times more compared to non-demented controls 
(FARRER  et  al.  1997).  The  E4  allele  of  the  apolipoprotein  E  (APOE)  gene  located  on 
chromosome 19 is the only recognized susceptibility gene for this late onset Alzheimer’s disease 
(GHARESOURAN et al. 2013b). 
Evidences  gathered  from  several  studies  suggest  that  a  mechanism  involving  an 
estrogen-signalling pathway may contribute to modulate risk for AD. A sex difference has been 
recognized in the prevalence of AD in women which cannot be exclusively accounted for by 
long life. There are some reports that the risk of developing AD and cognitive decline in women 
with a history of hormone replacement therapy (HRT) use during the postmenopausal period is 
lower (PAGANINI-HILL and HENDERSON 1996; TANG et al. 1996). 
The relationship between sex and APOE is also highlighted by the observation that 
women bearing at least one of 14 alleles present an increased risk of developing AD compared to 
men of the same APOE genotype (FARRER et al. 1997). Experimental evidences suggest that 
estrogen  protects  neuronal  cells  against  oxidative-stress,  improves  survival  of  hippocampal 
neurons, increases dendritic spine density on CA1 pyramidal neurons, and enhances cholinergic 
and serotonergic neurotransmission (MCEWEN 2001). In rodent tissues it has been shown that 
estrogen modulates the expression of Apolipoprotein E gene (APOE) (SRIVASTAVA et al. 1997) 
and  activates  synaptic  sprouting  in  response  to  injury  throughout  an  APOE-dependent 
mechanism (STONE et al. 1998). Neuroimaging data showed that ERT increases cerebral blood 
ﬂow and modulates brain activity (MAKI and RESNICK 2001). 
Estrogen has been shown to act as a neuroprotectant and neurotrophic agent. In vitro 
circumstance estrogen can increase APP secretion and prevents Ab1-42 aggregation. It is one 
family of sex hormones and exerts many of its effects during the activation of nuclear receptors 
(estrogen receptors, ERα and β) (ENMARK and GUSTAFSSON, 1999). The detection of ERα in the 
regions  of  the  brain  affected  by  AD  pathology  demonstrates  the  local  distribution  of  these 
receptors in the brain overlaps that of the neuro(MCEWEN and ALVES 1999; MITRA et al. 2003). 
The most important genetic risk factor for late-onset AD is the ε4 allele of the APOE 
(FARRER  et  al.  1997).  Previous  studies  showed  a  relation  between  ERα  PvuII  and  XbaI N. SOHRABIFAR et al: PVUII AND XBAI POLYMORPHISM AND LATE ONSET ALZHEIMER                     439 
polymorphisms  and  the  APOE  ε4  allele  in  increasing  the  risk  of  AD  (BRANDI  et  al.  1999; 
MATTILA et al. 2000). It is established that estrogen up-regulates the expression of apolipoprotein 
E (ApoE) gene (SRIVASTAVA et al. 1997) pathological lesions of AD, which has a role in the 
metabolism  of  b-amyloid  related  to  the  progress  of  Alzheimer’s  disease.  There  are  two 
polymorphic loci with only 50 bp apart in intron 1 of ER-α gene, Pvu II locus and Xba I locus 
(CASTAGNOLI et al. 1987).  These polymorphic loci may influence the expression of ER-α gene.  
Several  studies  have  examined  the  association  between  AD  and  ERα  gene  PvuII  and  XbaI 
polymorphisms. Some case-control studies have found an increased frequency of the PvuII and 
XbaI polymorphisms in AD subjects compared to controls (BRANDI et al. 1999; ISOE et al. 1997; 
JI et al. 2000). These ﬁndings suggest a role for ERα in the pathogenesis of AD. Studies in HeLa 
cells indicated that xp haplotype of ERα has higher expression than the XP one, but there was no 
significant difference between themes (MARUYAMA et al. 2000). 
Based  on  the  above  findings  implying  the  potential  importance  of  ER-α  in  the 
pathogenesis of AD and different frequency of related polymorphisms of the genes in various 
populations,  we studied  the  distribution  of ERα  PvuII  and XbaI  polymorphisms  in 160  AD 
patients as well as in 163 age and gender matched controls, in order to determine whether they 
influence the susceptibility on development of the disease in eastern Azerbaijan of Iran. 
MATERIALS AND METHODS 
Subjects sample Preparation  
The study included 160 AD patients (women & men, the mean age 76.06±7.75 year, 
ranging from 65 to 99 and healthy control group included 163 healthy individuals with the same 
ethnicity to subject group (women & men, the mean age 75.29±6.75 year, ranging from 65 to 89 
years) which were randomly selected from a diagnostic pathobiology lab. All Alzheimer subjects 
were diagnosed by expert clinicians according to the MMSE criteria (DOODY et al. 2001). The 
age of onset was above 65 years, and the sporadic form of the disease was ensured where no 
affected individuals were present in first degree relatives of subjects. All subjects included in the 
study were Azeri Turk originating from a limited population area in northwest of Iran. Samples 
of this study were used to evaluate several SNPs in other susceptible genes (GHARESOURAN et al. 
2013a; GHARESOURAN et al. 2013b; GHARESOURAN et al. 2014). 
 
DNA preparation and genotyping 
Blood specimens were collected in sterile tubes containing EDTA and the DNA was 
extracted  using  the  salting  out  method.  The  ERα  gene  polymorphism  identification  was 
determined by PCR/RFLP. Products of 1.3 kb long were obtained with a pair of primers (5'- 
CTG CCA CCC TAT CTG TAT CTT TTC CTA TTC TCC -3' and 5'- TCT TTC TCT GCC 
ACC CTG GCG TCG ATT ATC TGA -3'). The primer designing was carried out using online 
primer  3  software  and  Ensembl  Genome  Browser  used  for  blasting.  The  PCR  reaction  was 
prepared in a total volume of 25 µl, containing 0.1 µg of genomic DNA, 0.01 µg each of primers, 
2.5 µg of 10×PCR buffer (670  mM Tris-HCl pH 8.8, 160  mM (NH4)2SO4, 0.1%Tween-20), 
dNTP mix (10mM each), 50 mM MgCl2, Taq DNA polymerase (5000u/ml). After denaturation 
of  template  DNA  at  94°C  for  2  minutes,  30  cycles  of  PCR  reactions  were  optimized  and 
performed by  denaturation at 94°C  for  30  seconds, annealing at  68.5°C for  30seconds and 
extension  at  72°C  for  50  seconds.  The  PCR  products  were  digested  with  restriction 
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PCR products were digested using 2unit/µl of Pvu II and Xba I restriction enzyme in a total 
volume  of  25µl  in  separate  reactions,  containing  5µl  PCR  product  in  supplied  buffer.  The 
mixture was incubated at  37°C for 24h. The digested PCR  product was fractionated  on  8% 
polyacrylamide gel and visualized after staining by AgNo3.  Capital letters (P or X) denoted the 
absence of the restriction site, and small letters (p or x) denoted its presence.  The restriction 
endonucleases were purchased from Roche applied science. The purified PCR products from 21 
AD cases and 20 healthy controls were randomly sequenced bidirectionally. 
 
Statistical analysis 
Statistical  analysis  was  performed  using  the  Sigma  Stat  2.0  software.  Allelic  and 
genotypic  frequencies  were  obtained  by  direct  counting.  Fisher’s  exact  test  was  used  for 
differences in genotypes and haplotypes between the groups. Statistical significance was set at 
P< 0.05 and the odds ratio (OR) was calculated at 95% CI.  
 
RESULTS 
A  total  of  323  individuals  were  examined  in  the  present  study  to  evaluate  the 
association of ERα PvuII and XbaI polymorphisms in ERα gene with AD using PCR/RFLP 
procedure. The patient and control groups were matched by age, gender status.  
   The statistical analysis of patients, genotypes and allele frequencies (Table 1) indicated 
a significant difference in ERα genotype and allele frequencies between the AD patients and 
healthy  subjects.  When  PvuII  and  XbaI  RFLPs  were  analyzed  separately  we  observed  an 
increased prevalence of both PP (P< 0.001) and XX (P= 0.007) alleles in individuals affected 
with LOAD. When we grouped AD patients according to different ERα genotypes it revealed 
that there were no signiﬁcant differences in age at onset. 
 
Table1. Pvu II and Xba I polymorphism of ERa gene in the investigated groups. 
Genotype/Allele 
AD 
patients(N) 
Healthy controls 
(N) 
P-value  OR  95% CI  Power 
PvuII Allele                   
P  166(51%)  101(31%)  Reference group 
0.30-0.57 
89% 
P  154(49%)  225(69%)  <0.001  0.41   
PvuII Genotype                   
PP  36(22.5%)  16(9.8%)  Reference group 
Undefined 
Undefined 
Pp  94(58.8%)  69(42.3%) 
<0.001  Undefined 
 
Pp  30(18.8%)  78(47.8%)   
XbaI Allele             
X  95(29.7%)  58(17.8%)  Reference group 
0.35-0.74 
91% 
X  225(70.3%)  268(82.2%)  <0.001  0.51   
XbaI Genotype             
XX  27(16.9%)  11(6.7%)  Reference group 
Undefined 
Undefined 
Xx  41(25.6%)  36(22.1%) 
0.007  Undefined 
 
Xx  92(57.5%)  116(71.2%)   
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Using the PP or Pp genotype as a reference, the odds ratio for AD in subjects with pp 
genotype was 0.25 (95% CI =0.15 – 0.41). Using the XX or Xx genotype as a reference, the 
presence of the odds ratio for AD in subjects with xx genotype was 0.54 (95% CI =34 – 0.87) 
(Table2). 
After analysis of the combined genotypes of the two loci, 9 genotypes were obtained 
due to the linkage disequilibrium between the PvuII and XbaI loci several kinds of genotypes 
were infrequent in the genotyped individuals.  PPXx has a significantly more frequency in the 
LOAD patients than that in the control group. 
 
Table2.The sum of ins or del allele frequencies in patients and healthy controls 
Allelic 
frequencies 
AD 
patients(N) 
Healthy controls 
(N) 
P-value  OR  95% CI  Power 
PvuII Allele 
Pp  30(18.8%)  78(47.9%) 
<0.001 
 
0.25 
 
0.15-0.41 
 
93%  Pp + PP  130(81.2%)  85(52.1%) 
XbaI Allele 
Xx  92(57.5%)  116(71.2%)   
0/01 
 
0.54 
 
0.34-0.87 
 
88%  xX + XX  68(42.5%)  47(28.8%) 
 
DISCUSSION 
XbaI  and  PvuII  polymorphic  loci  were  found  in  the  intron  1  of  ER-α  gene.    It  is 
demonstreated that there are key regulation sequences such as enhancer and promotor sequences 
are  existed  in  this  region,  so  it  proposed  that  mutations  in  this  intron  may  influence  the 
expression and biological function of ER-α (HILL et al. 1989). 
Different  ER-α  genotypes  may  rather  determine  individual’s  differences  in  ER-α 
expression than influence the final effect of ER-α. In present study we found that subjects who 
had AD represented “p or x” allele and in AD patients, PPXX genotype frequency was not 
higher than that in the healthy patients significantly. According to the statistical analysis the 
ppxx  genotype  is clearly associated with AD as a “protective” factor.  A study that recently 
accomplished in UK proposed that px allele of ER-α might be a “protective” haplotype to AD 
(LAMBERT  et  al.  2001).    The  sample  size  was  not  large  enough  to  provide  an  accurate 
interpretation after stratification for gender and genotype. 
We did ﬁnd an association between the ERα PvuII and AD either a cumulative effect of 
XbaI and PvuII in contributing to increase the risk of AD. 
Among previous reports, several case-control studies reported a signiﬁcant association 
between PvuII and XbaI polymorphisms and AD (BRANDI et al. 1999; ISOE et al. 1997; JI et al. 
2000) Two Japanese case-control studies found higher frequencies of both PvuII P allele and PP 442                                                                                                            GENETIKA, Vol. 46, No.2, 437-444, 2014 
genotype or XbaI X allele and XX genotype in AD subjects compared to controls (ISOE et al. 
1997; JI et al. 2000). In an Italian sample Brandi et al., combining the alleles of the two ERα 
gene polymorphisms, demonstrated that the PPXX genotype was signiﬁcantly more frequent in 
AD than in controls (BRANDI et al. 1999). 
Our data confirm those reported by Brandi et al. in a dataset of Italian patients with AD. 
They found an increased frequency of both the X and P alleles of the ERα XbaI and PvuII 
polymorphisms in AD (BRANDI et al. 1999). Our results and several previous studies on the 
association  between  ERα  and  AD  confirm  this  hypothesis  (ISOE  et  al.  1997;  JI  et  al.  2000; 
MATTILA  et  al.  2000).  Differences  between  different  studies  may  have  several  reasons  like 
sample size and mode, different ethnical and geographical origins. Lastly, it is also possible that 
the increased risk of AD associated with ERα polymorphisms is due to linkage disequilibrium 
with linked genes that may cause and increased risk for developing AD. 
There are no functional studies that report functional effect of the ERα PvuII and XbaI 
polymorphisms  in  AD.  ERα  are  to  be  found  throughout  the  brain,  especially  in  structures 
implicated in learning and memory such as the CA1–CA3 region of the hippocampus (MITRA et 
al. 2003), which is early affected in AD (JELLINGER 1998). ERα has an intronic localization; they 
bind to the estrogen response element in the promoter region of target genes, with subsequent 
stimulation of the expression of speciﬁc genes involved in neuroprotective processes. Therefore, 
neurons  expressing  low  ERα  may  be  more  vulnerable  to  excitotoxins  and  free  radicals 
(MCEWEN  2001).  in  addition  it  is  demonstrated  that estrogens  have a  cognitive  enhancing 
effect and appear to be able to protect the brain from neurodegeneration (MCEWEN 2001). 
 
CONCLUSION 
This study confirms the hypothesis that ERα XbaI and PvuII polymorphism are associated with 
increased risk of LOAD. For investigation of Functional consequences of this polymorphism and 
mechanisms to which the ERα polymorphisms could lead to AD there must be fundamental 
studies at biochemical level to be established. 
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Izvod 
Vršena  su  istraživanja  160  bolesnih  (LOAD)  i  163  zdrava,  kontrolna  pacijenta  istog  pola  i 
starosti.  Za  utvrđivanje  polimorfizma PvuII  I  XbaI  kod  Alchajmerove  bolesti  primenjene  su 
PCR/RFLP metode a učestalost genotipova je utvrđivana statističkim metodama. Produkti PCR 
reakcije pripremljeni od 21 slučaja bolesnih i 20 zdravih kontrolnih pacijenata su prećišćeni I 
sekvencionirani  u  oba  pravca.  Utvrđena  je  veća  učestalost  mutiranih  alela  u  PvuII  I  XbaI 
lokusima kod LOAD (bolesne) grupe u odnosu na kontrolnu grupu (P<0.001, OR=0.51, 95 % CI 
0.35-0.74  za  XbaI  lokus;  P<0.001,  OR=0.41,  95  %  CI  0.3-0.57  za  PvuII  lokus).  Rezultati 
sugerišu  da  su  Era  XbaI  I  PVUII  polimorfizam  dodatni  faktori  rizika  za  kasnu  pojavu 
Alchajmerove bolesti. 
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